SCHEMBL22252315

SCHEMBL22252315

CCOC(=O)c1cnc2c(N(C)Cc3ccccc3)cc(-c3cn(C(C)C)c4ncccc34)nn12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TYK2 P29597 5/20 0.44
▸ MEN1 O00255 3/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ ATM Q13315 1/20 0.38
▸ LMNA P02545 3/20 0.37
▸ MAPT P10636 2/20 0.37
▸ CCND1 P24385 3/20 0.37
▸ CDK6 Q00534 3/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ MAOB P27338 1/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ POLB P06746 1/20 0.35
▸ ELANE P08246 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ PDE10A Q9Y233 1/20 0.34
▸ CYP1A2 P05177 2/20 0.34
▸ CYP3A4 P08684 2/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ GABRA1 P14867 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22252361 0.92 TYK2 (0.47) TYK2MEN1KMT2ACCND1CDK6
SCHEMBL22252603 0.90 TYK2 (0.47) TYK2CCND1CDK6ALDH1A1
SCHEMBL22252314 0.87 ELANE (0.37) TYK2MEN1KMT2AATMLMNA
SCHEMBL22252351 0.84 CDC7 (0.44) TYK2MEN1KMT2AATMLMNA
SCHEMBL22252367 0.84 TYK2 (0.41) TYK2ELANE
SCHEMBL22252355 0.84 TYK2 (0.52) TYK2LMNASMN1; SMN2
SCHEMBL22252615 0.83 TYK2 (0.42) TYK2
SCHEMBL22252614 0.83 TYK2 (0.42) TYK2
SCHEMBL22252210 0.83 TYK2 (0.42) TYK2
SCHEMBL22252375 0.82 TYK2 (0.56) TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11174264-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2021-11-16 — — US disclosed
US-20200231594-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-07-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11174264-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 TYK2 1/4885MEN1 2491/4885KMT2A 206/4885
US-20200231594-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TYK2 1/4885MEN1 2491/4885KMT2A 206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback